309 related articles for article (PubMed ID: 32623818)
61. Nusinersen in adult patients with spinal muscular atrophy: Observations from a single center.
Moshe-Lilie O; Visser A; Chahin N; Ragole T; Dimitrova D; Karam C
Neurology; 2020 Jul; 95(4):e413-e416. PubMed ID: 32665408
[TBL] [Abstract][Full Text] [Related]
62. Nusinersen for older patients with spinal muscular atrophy: A real-world clinical setting experience.
Veerapandiyan A; Eichinger K; Guntrum D; Kwon J; Baker L; Collins E; Ciafaloni E
Muscle Nerve; 2020 Feb; 61(2):222-226. PubMed ID: 31773738
[TBL] [Abstract][Full Text] [Related]
63. Intrathecal nusinersen treatment for SMA in a dedicated neuromuscular clinic: an example of multidisciplinary and integrated care.
Sansone VA; Albamonte E; Salmin F; Casiraghi J; Pirola A; Bettinelli M; Rao F; Mancini L; Tovaglieri N; Fedeli F; Stoia P; Heinen M; Cozzi V; Carraro E; Lunetta C; Di Bari A; Mercuri E;
Neurol Sci; 2019 Feb; 40(2):327-332. PubMed ID: 30430317
[TBL] [Abstract][Full Text] [Related]
64. Radiation dose reduction for CT-guided intrathecal nusinersen administration in adult patients with spinal muscular atrophy.
Cordts I; Deschauer M; Lingor P; Burian E; Baum T; Zimmer C; Maegerlein C; Sollmann N
Sci Rep; 2020 Feb; 10(1):3406. PubMed ID: 32099042
[TBL] [Abstract][Full Text] [Related]
65. Radiation exposure of image-guided intrathecal administration of nusinersen to adult patients with spinal muscular atrophy.
Oldenburg D; Guberina N; Stolte B; Kizina K; Stenzel E; Radbruch A; Kleinschnitz C; Hagenacker T; Forsting M; Mönninghoff C
Neuroradiology; 2019 May; 61(5):565-574. PubMed ID: 30868184
[TBL] [Abstract][Full Text] [Related]
66. Cone-beam computed tomography guided nusinersen administrations in adult spinal muscular atrophy patients with challenging access: a single- center experience.
Salapura V; Snoj Z; Leonardis L; Koritnik B; Kostadinova V
Radiol Oncol; 2022 Aug; 56(3):319-325. PubMed ID: 35962954
[TBL] [Abstract][Full Text] [Related]
67. Use of three-dimensional printing of a lumbar skeletal model for intrathecal administration of nusinersen: a brief technical report.
Abe H; Inoue R; Tsuchida R; Azuma K; Ino K; Konishi M; Hozumi J; Sumitani M
Reg Anesth Pain Med; 2020 Oct; 45(10):757-760. PubMed ID: 32817238
[TBL] [Abstract][Full Text] [Related]
68. Examining Real-World Adherence to Nusinersen for the Treatment of Spinal Muscular Atrophy Using Two Large US Data Sources.
Youn B; Proud CM; Wang N; Hou Q; Viscidi E; Eaton S; Paradis AD; Neville BA; Johnson NB
Adv Ther; 2023 Mar; 40(3):1129-1140. PubMed ID: 36645543
[TBL] [Abstract][Full Text] [Related]
69. Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy.
Orbach R; Sagi L; Sadot E; Tokatly Latzer I; Shtamler A; Zisberg T; Fattal-Valevski A
Muscle Nerve; 2022 Dec; 66(6):762-766. PubMed ID: 36214191
[TBL] [Abstract][Full Text] [Related]
70. Ethical Challenges Confronted When Providing Nusinersen Treatment for Spinal Muscular Atrophy.
Burgart AM; Magnus D; Tabor HK; Paquette ED; Frader J; Glover JJ; Jackson BM; Harrison CH; Urion DK; Graham RJ; Brandsema JF; Feudtner C
JAMA Pediatr; 2018 Feb; 172(2):188-192. PubMed ID: 29228163
[TBL] [Abstract][Full Text] [Related]
71. Ultrasound-guided interlaminar approach for nusinersen administration in patients with spinal muscular atrophy with spinal fusion or severe scoliosis.
Wei C; Liang Z; Wu Y; Liu S; Qiu J; Meng L; Li C; Li S; Bao X; Wang Z; Chen L; Xiong H
Orphanet J Rare Dis; 2023 Feb; 18(1):30. PubMed ID: 36800969
[TBL] [Abstract][Full Text] [Related]
72. Stability of serial platelet and urine protein measurements in patients receiving nusinersen for spinal muscular atrophy.
Nagarajan EK; Özütemiz C; Rubin N; Nascene DR
Muscle Nerve; 2022 Jul; 66(1):76-79. PubMed ID: 35466424
[TBL] [Abstract][Full Text] [Related]
73. Skip constructs in spinal muscular atrophy: outcomes of a novel approach for posterior spinal instrumentation and fusion.
Konigsberg MW; Matsumoto H; Ball JR; Roye BD; Vitale MG
Spine Deform; 2020 Oct; 8(5):1093-1097. PubMed ID: 32253736
[TBL] [Abstract][Full Text] [Related]
74. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps.
Gidaro T; Servais L
Dev Med Child Neurol; 2019 Jan; 61(1):19-24. PubMed ID: 30221755
[TBL] [Abstract][Full Text] [Related]
75. Nusinersen: First Global Approval.
Hoy SM
Drugs; 2017 Mar; 77(4):473-479. PubMed ID: 28229309
[TBL] [Abstract][Full Text] [Related]
76. Symptomatic intracranial hypertension in an adult patient with spinal muscular atrophy and arachnoid cysts receiving nusinersen.
Machetanz G; Grziwotz M; Semmler L; Maier M; Maegerlein C; Deschauer M
J Neuromuscul Dis; 2023; 10(4):719-725. PubMed ID: 37248913
[TBL] [Abstract][Full Text] [Related]
77. Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study.
Kiefer P; Kirschner J; Pechmann A; Langer T
Orphanet J Rare Dis; 2020 Jul; 15(1):194. PubMed ID: 32727502
[TBL] [Abstract][Full Text] [Related]
78. Physical Therapy and Nusinersen Impact on Spinal Muscular Atrophy Rehabilitative Outcome.
Mirea A; Leanca MC; Onose G; Sporea C; Padure L; Shelby ES; Dima V; Daia C
Front Biosci (Landmark Ed); 2022 Jun; 27(6):179. PubMed ID: 35748255
[TBL] [Abstract][Full Text] [Related]
79. Children and young adults with spinal muscular atrophy treated with nusinersen.
Osredkar D; Jílková M; Butenko T; Loboda T; Golli T; Fuchsová P; Rohlenová M; Haberlova J
Eur J Paediatr Neurol; 2021 Jan; 30():1-8. PubMed ID: 33307321
[TBL] [Abstract][Full Text] [Related]
80. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
Finkel RS; Mercuri E; Darras BT; Connolly AM; Kuntz NL; Kirschner J; Chiriboga CA; Saito K; Servais L; Tizzano E; Topaloglu H; Tulinius M; Montes J; Glanzman AM; Bishop K; Zhong ZJ; Gheuens S; Bennett CF; Schneider E; Farwell W; De Vivo DC;
N Engl J Med; 2017 Nov; 377(18):1723-1732. PubMed ID: 29091570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
